Login to Your Account



Cell Genesys Restructuring To Focus On GVAX Work

By Randall Osborne


Wednesday, June 8, 2005
Less than a month after getting a special protocol assessment from the FDA for the second Phase III trial with its GVAX prostate-cancer vaccine, Cell Genesys Inc. is restructuring to beef up its efforts with the vaccine in several indications while dropping others. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription